| Literature DB >> 20490353 |
Fábio Lera Orsatti1, Eliana Aguiar Petri Nahas, Jorge Nahas-Neto, Nailza Maesta, Cláudio Lera Orsatti, Cesar Edurado Fernandes.
Abstract
Objective. To investigate the independent and additive effects of resistance training (RT) and soy isoflavone (ISO) on body composition in postmenopausal women (PW). Method. This study used a placebo-controlled, double-blind (soy), randomized (ISO versus placebo) x (RT versus No RT) design. A total of 80 PW, aged 45-70 years, were randomly (71 completed 9-months intervention): RT + ISO (n = 15), No RT + ISO (n = 20), RT + placebo (n = 18), and No RT + placebo (n = 18). ISO received 100 mg a day of isoflavone; and to RT attended supervised resistance training sessions. At baseline and 9-months, fat and muscle mass were estimated by DXA. ANOVA and test t were used. Results. RT groups showed significantly increased muscle strength (35.2%) and muscle mass (1.4%). Exercising attenuated gains in fat trunk and % body fat (P < .05). Significant decreases in muscle mass (-1.8%) and increases in fat mass of the whole-body (1.6%) and trunk (9.7%) was found in no-RT groups (P < .05). In ISO groups, there were no differences in body composition and muscle strength. ISO and RT had no additive effects. Conclusion. In PW: RT improved muscle mass and strength and attenuated gain of fat mass; ISO did not alter body composition and muscle strength; there were no additive effects of RT and ISO.Entities:
Year: 2010 PMID: 20490353 PMCID: PMC2872758 DOI: 10.1155/2010/156037
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Baseline clinical characteristics of 71 postmenopausal women (mean ± SD).
| Variables | RT + ISO | RT + P | No RT + ISO | No RT + P |
|
|---|---|---|---|---|---|
| ( | ( | ( | ( | ||
| Age (years) | 55.7 ± 7.0 | 56.6 ± 8.8 | 56.0 ± 5.8 | 55.3 ± 8.0 | .99 |
| Postmenopause (years) | 7.7 ± 5.3 | 8.7 ± 6.1 | 6.5 ± 4.9 | 7.7 ± 6.2 | .64 |
| FSH (mUI/mL) | 74.0 ± 27.7 | 71.8 ± 24.3 | 63.0 ± 21.1 | 63.3 ± 21.3 | .15 |
| E2 (pg/mL) | 23.1 ± 4.8 | 21.7 ± 4.3 | 22.5 ± 4.8 | 23.3 ± 5.8 | .59 |
| Weight (kg) | 73.2 ± 15.1 | 62.8 ± 9.8(a) | 75.0 ± 12.9(a) | 73.7 ± 12.6 | .03 |
| Height (cm) | 154.9 ± 7.0 | 154.7 ± 5.6 | 158.1 ± 5.8 | 155.6 ± 5.2 | .27 |
| WC (cm) | 95.7 ± 10.1 | 87.3 ± 7.7 | 94.1 ± 12.3 | 95.1 ± 11.9 | .09 |
| BMI (kg/m2) | 30.3 ± 4.7 | 26.0 ± 3.0(a) | 30.1 ± 4.7 | 30.4 ± 5.3(a) | .03 |
| MM (kg) | 34.0 ± 6.2 | 30.3 ± 4.1 | 34.0 ± 4.2 | 33.6 ± 4.0 | .08 |
| MM-Limbs (kg) | 13.6 ± 2.8 | 12.0 ± 1.9 | 13.7 ± 2.0 | 13.6 ± 2.0 | .08 |
| MM (%) | 52.2 ± 4.5 | 54.3 ± 4.2 | 51.2 ± 6.2 | 51.0 ± 5.1 | .20 |
| Trunk fat mass (kg) | 14.3 ± 4.4 | 12.3 ± 3.2 | 15.8 ± 5.4 | 14.8 ± 4.4 | .11 |
| Body fat (%) | 46.2 ± 4.9 | 43.0 ± 4.4 | 46.8 ± 6.7 | 46.5 ± 5.7 | .12 |
| Strength muscle (kg) | 30.7 ± 9.2 | 31.3 ± 6.8 | 33.0 ± 10.2 | 32.7 ± 7.9 | .15 |
FSH: follicle-stimulating hormone; E2: estradiol; WC: waist circumference; BMI: body mass index; MM: muscle mass; SD: standard deviations; ISO: isoflavone; PL: placebo; RT: resistance training.
*Significant difference among groups (P < .05) (one-way ANOVA),(a)With significantly difference between groups (P < .05).
Figure 1Percent changes in muscle strength (leg extension) from baseline to 9 months in response to exercise and isoflavone. ANOVA (p): ISO × Time = 0.82. RT × Time = 0.02. Interaction = 0.86.
Effects of soy (ISO) and/or exercise (RT) on body composition (fat and muscle mass) in the study groups at baseline and at 9 months (mean ± SD).
| Variables | RT + ISO | RT + P | No RT + ISO | No RT + P |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| MM (Kg) | ||||
| Baseline | 34.0 ± 6.2 | 30.3 ± 4.1 | 34.0 ± 4.2 | 33.6 ± 4.0 |
| After 9 months | 34.6 ± 6.1 | 30.6 ± 3.7 | 33.2 ± 3.8 | 33.1 ± 4.1 |
| ANOVA (p) | ||||
| ISO × Time | 0.61 | |||
| RT × Time | <0.01 | |||
| Interaction | 0.19 | |||
| Limb-MM (kg) | ||||
| Baseline | 13.6 ± 2.8 | 12.0 ± 1.9 | 13.7 ± 2.0 | 13.6 ± 2.0 |
| After 9 months | 14.2 ± 2.9 | 12.3 ± 1.9 | 13.7 ± 2.2 | 13.4 ± 1.9 |
| ANOVA (p) | ||||
| ISO × Time | 0.05 | |||
| RT × Time | <0.00 | |||
| Interaction | 0.67 | |||
| MM (%) | ||||
| Baseline | 52.2 ± 4.5 | 54.3 ± 4.2 | 51.2 ± 6.2 | 51.0 ± 5.1 |
| After 9 months | 52.4 ± 4.8 | 54.3 ± 5.0 | 50.0 ± 6.0 | 50.3 ± 5.6 |
| ANOVA (p) | ||||
| ISO × Time | 0.79 | |||
| RT × Time | 0.04 | |||
| Interaction | 0.48 | |||
| Trunk fat mass (kg) | ||||
| Baseline | 14.3 ± 4.4 | 12.3 ± 3.2 | 15.8 ± 5.4 | 14.8 ± 4.4 |
| After 9 months | 15.4 ± 5.3 | 12.9 ± 3.7 | 17.2 ± 6.1 | 16.7 ± 5.6 |
| ANOVA (p) | ||||
| ISO × Time | 0.96 | |||
| RT × Time | 0.04 | |||
| Interaction | 0.28 | |||
| Whole-body fat mass (kg) | ||||
| Baseline | 31.1 ± 10.3 | 24.8 ± 6.2 | 32.2 ± 9.7 | 31.3 ± 8.8 |
| After 9 months | 31.8 ± 10.0 | 25.6 ± 7.4 | 33.8 ± 10.7 | 32.8 ± 9.2 |
| ANOVA (p) | ||||
| ISO × Time | 0.94 | |||
| RT × Time | 0.12 | |||
| Interaction | 0.85 | |||
| Body fat (%) | ||||
| Baseline | 46.2 ± 4.9 | 43.0 ± 4.4 | 46.8 ± 6.7 | 46.5 ± 5.7 |
| After 9 months | 45.6 ± 5.1 | 43.8 ± 5.8 | 48.4 ± 6.8 | 48.0 ± 6.1 |
| ANOVA (p) | ||||
| ISO × Time | 0.25 | |||
| RT × Time | 0.02 | |||
| Interaction | 0.20 |
Daidzein and genistein plasma levels at 9 months of intervention (mean ± SD).
| Parameter | Isoflavone | Placebo |
|
|---|---|---|---|
| ( | ( | ||
| Daidzein ( | 220.4 ± 53.5 | 125.4 ± 27.9 | <.0001 |
| Genistein ( | 144.3 ± 50.5 | 68.1 ± 19.5 | <.0001 |
*Significant difference among groups (P < .05) (independent t-test).